Atomoxetine for amphetamine-type stimulant dependence during buprenorphine treatment: A randomized controlled trial.

ABSTRACT: BACKGROUND:Amphetamine type stimulants (ATS) use is highly prevalent and frequently co-occurs with opioid dependence in Malaysia and Asian countries. No medications have established efficacy for treating ATS use disorder. This study evaluated the safety, tolerability, and potential efficacy of atomoxetine for treating ATS use disorder. METHODS:Participants with opioid and ATS dependence (N = 69) were enrolled in a pilot, double-blind, placebo-controlled randomized clinical trial; all received buprenorphine/naloxone and behavioral counseling and were randomized to atomoxetine 80 mg daily (n = 33) or placebo (n = 33). The effect size of the between-group difference on the primary outcome, proportion of ATS-negative urine tests, was estimated using Cohen's d for the intention-to-treat (ITT) s

SUBMITTER: Schottenfeld RS 

PROVIDER: S-EPMC5911201 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature